Replies to post #128101 on Amarin Corp Plc (AMRN)

[ggwpq]

JL, thanks for the feedback. Clearly, AMRN long on this board has a variant perception, thanks to you, of R-I success than the average CVD professionals and hence the market.

The following link (p.29) has the inclusion criteria for the FOURIER trial, You may find it interesting to contrast it with that of R-I.

https://www.nejm.org/doi/suppl/10.1056/NEJMoa1615664/suppl_file/nejmoa1615664_appendix.pdf


https://onlinelibrary.wiley.com/doi/full/10.1002/clc.22692

[Biobillionair]

JELIS is very predictive

Agreed, RRR~40% is what estimates now show, but the World will not believe until the trial is scrutinized for years. Amarin will be lucky to get on-label indication by 2020.

BB